Showing results (91-100 of 205) with videos related to
Sort By:
Pageof 21
Plos One|October 25, 2011
Auto-antibodies to β-F1-ATPase and vimentin in malignant mesotheliomaJenette Creaney, Ian M Dick, Deborah Yeoman, et al.Virology|March 1, 1991
Peptide mapping of neutralizing and nonneutralizing epitopes of duck hepatitis B virus pre-S polypeptideS Yuasa, R C Cheung, Q Pham, et al.Expert Opinion on Biological Therapy|July 30, 2005
Gene therapy of mesotheliomaDelia J Nelson, Bruce W S Robinson, Jane Allan, et al.Seminars in Oncology|February 12, 2002
New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agentsAnna K Nowak, Richard A Lake, Hedy Lee Kindler, et al.Cancer Immunology, Immunotherapy : CII|November 12, 2005
Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumorsChristine S Bundell, Connie Jackaman, Andreas Suhrbier, et al.International Immunology|February 23, 2012
IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phaseConnie Jackaman, Sally Lansley, Jane E Allan, et al.Cell|November 16, 1990
The hepatitis B virus-encoded transcriptional trans-activator hbx appears to be a novel protein serine/threonine kinaseJ Y Wu, Z Y Zhou, A Judd, et al.Antimicrobial Agents and Chemotherapy|December 1, 1979
Effects of interferon and adenine arabinoside treatment of hepatitis B virus infection on cellular immune responsesB Hafkin, R B Pollard, M L Tiku, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 16, 2004
Changes in weight and lean body mass during highly active antiretroviral therapyC M Shikuma, R Zackin, F Sattler, et al.Lung Cancer (Amsterdam, Netherlands)|October 29, 2013
Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesotheliomaJenette Creaney, Ian M Dick, Amanda Segal, et al.Pageof 21